Trial reportJournal of neuro-oncology2022
Initial results of a phase II trial of
Trial report in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Scientometric analysis of glioblastoma and blood-brain barrier research (1995-2024): evolving trends and therapeutic challenges.Frontiers in oncology · 2025Pooled it
- Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.Current oncology reports · 2025Article
- Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey.European journal of nuclear medicine and molecular imaging · 2025Article
- Complex Diagnostic Challenges in Glioblastoma: The Role ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Manufacturing 6-[Organic letters · 2024Article
- Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence.Journal of personalized medicine · 2024Review
- Review
- Evolving concepts in margin strategies and adaptive radiotherapy for glioblastoma: A new future is on the horizon.Neuro-oncology · 2024Review
- Integrating multi-modal imaging in radiation treatments for glioblastoma.Neuro-oncology · 2024Review
- Feasibility of [European journal of nuclear medicine and molecular imaging · 2023Article
- Results from a phase I study of 4-Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn-field high-grade glioma (HGG) recurrence is a common challenge with limited treatment options, including re-irradiation. The radiotracer 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (
methodsAdults with recurrent or progressive HGG previously treated with radiation were eligible. The primary endpoint was a 20% improvement from the historical control PFS at 3 months (PFS3) of 20% with systemic therapy alone. Re-RT dose was 35 Gy in 10 fractions. The target volume was MRI T1 contrast-enhancement defined tumor plus
resultsTwenty patients completed treatment per protocol. Diagnosis was most commonly glioblastoma, IDH-wildtype (60%). MRI-defined volumes were expanded by a median 43% (0-436%) by utilizing
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.